## **Supplementary Information**

Supplementary Figures 1–7 and Supplementary Table 1

## Extracellular bacterial lymphatic metastasis drives Streptococcus pyogenes systemic infection

Matthew K. Siggins<sup>1,2\*</sup>, Nicola N. Lynskey<sup>1,2</sup>, Lucy E. Lamb<sup>1</sup>, Louise A. Johnson<sup>3</sup>, Kristin K. Huse<sup>1,2</sup>, Max Pearson<sup>1,2</sup>, Suneale Banerji<sup>3</sup>, Claire E. Turner<sup>1</sup>, Kevin Woollard<sup>4</sup>, David G. Jackson<sup>3</sup>, Shiranee Sriskandan<sup>1,2\*</sup>

\*Correspondence: M.K.S (<u>m.siggins@imperial.ac.uk</u>) and S.S (<u>s.sriskandan@imperial.ac.uk</u>)

<sup>1</sup>Department of Infectious Disease, Imperial College London, W12 ONN, UK.

<sup>2</sup>MRC Centre for Molecular Bacteriology and Infection, Imperial College London, SW7 2DD, UK.

<sup>3</sup>MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, OX3 9DS, UK.

<sup>4</sup>Centre for Inflammatory Disease, Department of Immunology & Inflammation, Imperial College London, W12 0NN, UK.









Imaged area



- LN that does not receive lymph from injection site
- Lymphatic vessel that receives lymph from injection site

### Organs analysed

Receives lymph from injection site ig: Inguinal lymph node (ipsilateral) il: Iliac lymph node (ipsilateral) ax: Axillary lymph node (ipsilateral) ht: Heart (via subclavian vein)

Does not receive lymph from injection site br: Brachial lymph node (ipsilateral) lv: Liver

sp: Spleen

cax: Axillary lymph node (contralateral) cbr: Brachial lymph node (contralateral) cil: Iliac lymph node (contralateral) cig: Inguinal lymph node (contralateral) Injection site (i.m.)

- Pathway of lymphatic drainage
- Receives lymph from injection site
- Does not receive lymph from injection site

**Supplementary Fig. 1 | Lymphatic drainage routes demonstrated by Evans Blue. a–d**, Photographs showing drainage routes of Evans Blue dye following intramuscular injection into the hindleg (**a**, **b**, **d**) or subcutaneous injection into the tail (**c**) of mice. In-picture schematics show photographed area and injection site. **e**, Schematic showing summary of drainage following intramuscular injection into the hindleg. Data are representative of three independent experiments.







Supplementary Fig. 2 | Lymphatic-dominated dissemination of *S. pyogenes*. a, Bacterial counts recovered from the infection site, draining ipsilateral and non-draining ipsilateral lymph nodes of BALB/c mice, 3 h after intramuscular infection into the hindlimb with  $10^8$  CFU of a range of *S. pyogenes* isolates comprising of different *emm*-types. Symbols represent individual mice, *n* = 4 per group, and grey bar heights indicate geometric means. b, Bacterial counts recovered from the infection site, draining ipsilateral and non-draining ipsilateral lymph nodes of FVB/n mice, 3 h after intramuscular infection into the hindlimb with  $10^8$  CFU of logarithmic (blue) or stationary (red) phase *S. pyogenes* H598. Symbols represent individual mice, *n* = 3 per group, and bar heights indicate geometric means. c, d Bacterial counts recovered from draining- (inguinal, iliac, axillary) and non-draining (brachial) ipsilateral lymph nodes (c) and spleens (d) of FVB/n mice, 3 h after intramuscular infection into the hindlimb with  $10^4$ - $10^8$  CFU, as stipulated, of hypervirulent *S. pyogenes* H598. Symbols represent individual mice, *n* = 3 (Spleen) per group and bar heights indicate geometric means. Source data are provided as a Source Data file.

Imaging area Uninfected Imaging setup а Lymphatic vessels Transmitted light Blood vessels Inguinal LN IM injection of IM SYTO 62-labelled ∆capsule S. pyogenes SYTO 62 alone Direct staining of murine blood cells





Transmitted light: Lymphatic vessel Blood vessel

Antibody labelling of cells in efferent lymph



CD3<sup>+</sup> CD11b<sup>+</sup> B220<sup>+</sup> Transmitted light Blood vessel

### Supplementary Fig. 3 | Intravital confocal microscopy imaging of efferent lymphatic vessel. a,

Photograph of anaesthetized mouse on microscope set up for imaging. **b**, Photograph of flank vasculature with imaging area, including the imaging area of the efferent lymphatic that links the inguinal and axillary lymph nodes, highlighted in yellow. c-e, Fluorescent and transmitted light intravital confocal microscopy image of an efferent lymphatic vessel between inguinal and axillary lymph nodes, prior to injection (c), or following intramuscular injection of 5  $\mu$ M SYTO 62 (d) — a nucleic acid dye used to label bacteria in intravital microscopy experiments — or 10<sup>8</sup> CFU of SYTO 62 labelled capsule-deficient S. pyogenes (e). Lymph is labelled with FITC-conjugated dextran and appears blue (c-e), blood is labelled with TRITC-conjugated dextran and appears red (c). Scale bar

# g





**SYTO 62** 

represents 200  $\mu$ m. Supplementary Movie 1 shows blood and lymph flow in distinct vessels in the flank. **f**, **g**, Murine blood cells labelled directly with 30  $\mu$ M DAPI (**f**), or 5  $\mu$ M SYTO 62 (**g**), both demonstrate concentrated staining of nucleus without cytoplasmic or punctate staining. Scale bars represent 10  $\mu$ m. **h**, **i**, Representative fluorescent and transmitted light intravital confocal microscopy image of an efferent lymphatic vessel and blood vessels with cells stained for CD3 (red), B220 (cyan), and CD11b (blue) after infection with hypervirulent *S. pyogenes*. Scale bar represents 200  $\mu$ m (**h**) and 100  $\mu$ m (**i**). Imaging data are representative of three independent experiments.





**Supplementary Fig. 4** | **Dissemination of** *S. pyogenes* **in late infection. a**, **b**, Immunofluorescence staining of cryosections from the distant draining (**a**) and non-draining (**b**) axillary lymph nodes of FVB/n mice 24 h after intramuscular infection into the hindlimb with 10<sup>8</sup> CFU of *S. pyogenes* H1565 (green); Neutrophils (red); DAPI (blue); and High Endothelial Venules (magenta, **c** only). Scale bars: 200  $\mu$ m (**a**), 50  $\mu$ m (**b**). Imaging data are representative of five independent experiments. **LYVE-1 augments retention of encapsulated** *S. pyogenes* within lymph nodes. **c**–**e**, Blocking LYVE-1 impairs lymphatic-retention of encapsulated *S. pyogenes* and promotes systemic bacterial spread: High-Capsule  $\Delta$ P2 (H1458) recovered from the infection site (**c**), ipsilateral draining-lymph nodes (**d**), or systemic organs (**e**) of FVB/n mice injected intraperitoneally with a LYVE-1 blocking (red circles) or control antibody (grey circles) 24 h prior to a 3-h intramuscular infection with 10<sup>8</sup> CFU. Symbols represent individual mice, *n* = 9 per group, black lines indicate geometric means. \*p ≤ 0.05; \*\*\*p ≤ 0.001; ns, p > 0.5. Inguinal, p = 0.0009; Axillary, p = 0.0070; Blood, p = 0.0430; Spleen, p = 0.0140; Liver, p = 0.0243; Two-tailed Mann-Whitney test. Source data are provided as a Source Data file.



SpyCEP+



∆SpyCEP



## **Supplementary Fig. 5 | Role of SpyCEP and neutrophils in lymphatic dissemination.** a, Internalisation of *S. pyogenes* strains by human neutrophils after 30 minutes co-incubation at a multiplicity of infection of 10 bacteria: 1 neutrophil, measured by flow cytometry. Symbols represent

individual data points, n = 4; height of red bars indicate means and error bars represent standard error of the mean. **b**–**g**, Immunofluorescence images of cryosections from the local draining lymph nodes of FVB/n mice 24 h after intramuscular infection into the hindlimb with 10<sup>8</sup> CFU of *S*. *pyogenes* SpyCEP<sup>+</sup> H1565 (**b**–**d**) or  $\Delta$ SpyCEP H1567 (**e**–**g**). Orthogonal views of a 12 µm confocal *z*stack (**h**); *S. pyogenes* (green), neutrophils (red), DAPI (blue). Scale bars: 20 µm (**h**), 50 µm (**c**, **d**, **f**, **g**), 500 µm (**b**, **e**). Imaging data are representative of five independent experiments. **i**, Bacterial counts recovered from the infection site, draining lymph nodes and spleens of C57BL/6 mice, 3 h after intramuscular infection into the hindlimb with 10<sup>8</sup> CFU of wildtype *L. lactis* (blue circles), or *L. lactis* expressing SpyCEP (red circles). Symbols represent individual mice, n = 3 per group, and black lines indicate geometric means. \*\*\*\*p ≤ 0.0001 \*\*\*p ≤ 0.001. Leg, p = <0.0001; Inguinal, p = <0.0001; Axillary, p = 0.0005; Spleen, p = 0.0008; Two-tailed Student's t-test performed on log<sub>10</sub>-transformed data. Source data are provided as a Source Data file.

### Lymph node macrophages



Supplementary Fig. 6 | Macrophages exhibit limited phagocytosis and killing of *S. pyogenes*. a, b, Immunofluorescence staining of CD169<sup>+</sup> macrophages in cryosections from the local draining lymph nodes of FVB/n mice 96 h after hindlimb and tail subcutaneous injections of PBS (a) or clodronate liposomes (b); CD169 (yellow), DAPI (blue) Scale bars: 100  $\mu$ m. Imaging data are representative of three independent experiments c, grey bars show viable intracellular *S. pyogenes* strains as a percentage of original inoculum, determined by gentamicin protection assay (GPA) following 3 h of co-incubation of *S. pyogenes* with murine immortalised bone marrow-derived macrophages (multiplicity of infection 10:1). d, e, percentage of macrophages with internalised *S. pyogenes* (blue bars, d) and macrophage viability (e, green bars), both measured by flow cytometry after 3 h of coincubation of *S. pyogenes* with murine immortalised bone marrow-derived macrophages (multiplicity of infection 10:1). Symbols represent individual data points, n = 5 (a) or n = 3 (b, c); bar height indicates mean and error bars represent standard error of the mean. Source data are provided as a Source Data file.



Supplementary Fig. 7 | Representative gating strategies for flow cytometry. a, single cell suspensions from lymph nodes and blood were gated by singlets, size, then live CD45<sup>+</sup> cells were determined. Neutrophils were identified by further gating on CD11b and Ly6G: approach used for Fig. 5b. b, Neutrophils isolated from human blood were gated by size and then levels of internalised fluorescently-labelled *S. pyogenes* measured by gating on OG-488: approach used for Supplementary Fig. 5a. c, cultured iBMDM were gated by singlets, size, then live CD11b<sup>+</sup> cells were determined. Level of internalised fluorescently labelled *S. pyogenes* was measured in these cells by gating on OG-488: approach used for OG-488: approach used for Supplementary Fig. 5a. c, cultured iBMDM were gated by singlets, size, then live CD11b<sup>+</sup> cells were determined.

## Supplementary Table 1 | Bacterial strains used in this study

Species	Strain ID	<i>emm</i> type / strain	Description	Reference
S. pyogenes	H598	emm1	Hypervirulent, M1T1 invasive necrotising fasciitis isolate with natural <i>covS</i> mutation	1
S. pyogenes	H305	emm1	Scarlet fever M1T1 throat isolate (NCTC8198)	2
S. pyogenes	H330	emm3	Invasive puerperal sepsis blood isolate	3
S. pyogenes	H395	emm89	Invasive pneumonia blood isolate	4
S. pyogenes	H566	emm18	Invasive isolate, naturally highly encapsulated	5
S. pyogenes	H636	emm89	Invasive chest sepsis isolate	4
S. pyogenes	H584	emm1	M1T1 invasive puerperal sepsis blood isolate	1
S. pyogenes	H1454	emm1	Hyaluronan capsule deletion mutant of H584	This study
S. pyogenes	H1458	emm1	Highly encapsulated, hyaluronan capsule promoter P2 mutant of H584, selected in lymph node in vivo	6
S. pyogenes	H1565	emm1	Hypervirulent, highly encapsulated mutant of H584 with <i>covR</i> mutation, selected in spleen in vivo	6
S. pyogenes	H1567	emm1	SpyCEP deletion mutant of H1565	This study
E. coli		XL-10 gold		Agilent
L. lactis	H486	NZ9000	with control plasmid pDestErm	7
L. lactis	H487	NZ9000	with SpyCEP expression plasmid pcepA	7

## **Supplementary References**

- 1. Turner CE, *et al.* Molecular analysis of an outbreak of lethal postpartum sepsis caused by Streptococcus pyogenes. *J Clin Microbiol* **51**, 2089-2095 (2013).
- 2. Sriskandan S, Unnikrishnan M, Krausz T, Cohen J. Molecular analysis of the role of streptococcal pyrogenic Exotoxin A (SPEA) in invasive soft-tissue infection resulting from Streptococcus pyogenes. *Mol Microbiol* **33**, 778-790 (1999).
- 3. Afshar B, *et al.* Enhanced nasopharyngeal infection and shedding associated with an epidemic lineage of emm3 group A Streptococcus. *Virulence*, 1-11 (2017).
- 4. Turner CE, et al. Emergence of a New Highly Successful Acapsular Group A Streptococcus Clade of Genotype emm89 in the United Kingdom. *MBio* **6**, e00622 (2015).
- 5. Lynskey NN, *et al.* RocA truncation underpins hyper-encapsulation, carriage longevity and transmissibility of serotype M18 group A streptococci. *PLoS Pathog* **9**, e1003842 (2013).
- 6. Lamb LE, *et al.* Impact of contusion injury on intramuscular emm1 group a streptococcus infection and lymphatic spread. *Virulence* **9**, 1074-1084 (2018).
- 7. Zinkernagel AS, *et al.* The IL-8 protease SpyCEP/ScpC of group A Streptococcus promotes resistance to neutrophil killing. *Cell Host Microbe* **4**, 170-178 (2008).